Mauna Kea Technologies Cuts Debt, Boosts U.S. Sales in FY 2025 Turnaround
Event summary
- Mauna Kea Technologies reduced debt by €27 million through a court-supervised safeguard procedure.
- FY 2025 revenue grew 7% to €8.2 million, driven by a 38% increase in U.S. sales.
- Operating cash burn decreased by 34% to €4.2 million, excluding licensing revenues.
- Q1 2026 core product sales surged 68% year-over-year, with U.S. system placements up 85%.
- Net profit reached €10.8 million in 2025, reversing a €10.4 million loss in 2024.
The big picture
Mauna Kea Technologies' debt restructuring and improved U.S. sales performance mark a strategic inflection point, positioning the company for profitability. The medical device sector continues to favor technologies that enhance real-time diagnostics, and Mauna Kea's Cellvizio platform is gaining traction in key indications like pancreatic cysts and food intolerances. The company's ability to scale operations and maintain cost discipline will be critical as it navigates post-restructuring growth.
What we're watching
- U.S. Market Momentum
- Whether Mauna Kea can sustain its 34% constant currency growth in the U.S., its largest market.
- International Expansion
- The pace at which CellTolerance drives growth outside the U.S., particularly in EMEA and ROW.
- Regulatory Tailwinds
- How new CE Mark approvals under MDR and other regulatory clearances will accelerate international sales.
Related topics